Molecular Cancer Therapeutics: 10 (8)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther August 1 2011 10 (8) 1309-1309;

Spotlight on Clinical Response

Spotlight on Clinical Response

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Elizabeth De Oliveira, Belen Rubio-Viqueira, Steven Strawn, Michael J. Wick, James Martell and David Sidransky

Mol Cancer Ther August 1 2011 10 (8) 1311-1316; DOI:10.1158/1535-7163.MCT-11-0233

Therapeutic Discovery

Therapeutic Discovery

Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling

Batya Barkan, Yoel Kloog and Marcelo Ehrlich

Mol Cancer Ther August 1 2011 10 (8) 1317-1326; DOI:10.1158/1535-7163.MCT-10-1087
Therapeutic Discovery

Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase

Chun-Te Chen, Hirohito Yamaguchi, Hong-Jen Lee, Yi Du, Heng-Huan Lee, Weiya Xia, Wen-Hsuan Yu, Jennifer L. Hsu, Chia-Jui Yen, Hui-Lung Sun, Yan Wang, Edward T.H. Yeh, Gabriel N. Hortobagyi and Mien-Chie Hung

Mol Cancer Ther August 1 2011 10 (8) 1327-1336; DOI:10.1158/1535-7163.MCT-10-1117
Therapeutic Discovery

MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration

Zhenfeng Duan, Edwin Choy, David Harmon, Xianzhe Liu, Michiro Susa, Henry Mankin and Francis Hornicek

Mol Cancer Ther August 1 2011 10 (8) 1337-1345; DOI:10.1158/1535-7163.MCT-11-0096
Therapeutic Discovery

Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer

Jing Li, Bo Cao, Xichun Liu, Xueqi Fu, Zhenggang Xiong, Li Chen, Oliver Sartor, Yan Dong and Haitao Zhang

Mol Cancer Ther August 1 2011 10 (8) 1346-1356; DOI:10.1158/1535-7163.MCT-10-0985
Therapeutic Discovery

High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion

Laura Muinelo-Romay, Eva Colas, Jorge Barbazan, Lorena Alonso-Alconada, Marta Alonso-Nocelo, Marta Bouso, Teresa Curiel, Juan Cueva, Urbano Anido, Jeronimo Forteza, Antonio Gil-Moreno, Jaume Reventos, Rafael Lopez-Lopez and Miguel Abal

Mol Cancer Ther August 1 2011 10 (8) 1357-1366; DOI:10.1158/1535-7163.MCT-10-1019
Therapeutic Discovery

Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors

Wenle Xia, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, Jia He, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, Timothy M. Clay, Kimberly L. Blackwell, Herbert K. Lyerly and Neil L. Spector

Mol Cancer Ther August 1 2011 10 (8) 1367-1374; DOI:10.1158/1535-7163.MCT-10-0991
Therapeutic Discovery

Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues

Zhixia Zhou, Cai Zhang, Chengfeng Xia, Wenlan Chen, Huawei Zhu, Pingping Shang, Fang Ma, Peng George Wang, Jian Zhang, Wenfang Xu and Zhigang Tian

Mol Cancer Ther August 1 2011 10 (8) 1375-1384; DOI:10.1158/1535-7163.MCT-11-0030

Preclinical Development

Preclinical Development

Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells

Ayesha B. Alvero, Michele K. Montagna, Jennie C. Holmberg, Vinicius Craveiro, David Brown and Gil Mor

Mol Cancer Ther August 1 2011 10 (8) 1385-1393; DOI:10.1158/1535-7163.MCT-11-0023
Preclinical Development | Free Article

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew, Andy Cooke, Yan Yao, Christine Mantis, Jennifer Kahler, Jennifer Workman, Mark Bittner, Lorina Dudkin, David M. Epstein, Neil W. Gibson, Robert Wild, Lee D. Arnold, Peter J. Houghton and Jonathan A. Pachter

Mol Cancer Ther August 1 2011 10 (8) 1394-1406; DOI:10.1158/1535-7163.MCT-10-1099
Preclinical Development

Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Aleksandra Bielen, Lara Perryman, Gary M. Box, Melanie Valenti, Alexis de Haven Brandon, Vanessa Martins, Alexa Jury, Sergey Popov, Sharon Gowan, Sebastien Jeay, Florence I. Raynaud, Francesco Hofmann, Darren Hargrave, Suzanne A. Eccles and Chris Jones

Mol Cancer Ther August 1 2011 10 (8) 1407-1418; DOI:10.1158/1535-7163.MCT-11-0205
Preclinical Development

Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes

Arun Kanakkanthara, Anja Wilmes, Aurora O'Brate, Daniel Escuin, Ariane Chan, Ada Gjyrezi, Janet Crawford, Pisana Rawson, Bronwyn Kivell, Peter T. Northcote, Ernest Hamel, Paraskevi Giannakakou and John H. Miller

Mol Cancer Ther August 1 2011 10 (8) 1419-1429; DOI:10.1158/1535-7163.MCT-10-1057
Preclinical Development

Sodium Butyrate Inhibits the Self-Renewal Capacity of Endometrial Tumor Side-Population Cells by Inducing a DNA Damage Response

Kiyoko Kato, Aya Kuhara, Tomoko Yoneda, Takafumi Inoue, Tomoka Takao, Tatsuhiro Ohgami, Li Dan, Ayumi Kuboyama, Soshi Kusunoki, Satoru Takeda and Norio Wake

Mol Cancer Ther August 1 2011 10 (8) 1430-1439; DOI:10.1158/1535-7163.MCT-10-1062
Preclinical Development

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a Kras^G12D;Pten Deletion Mouse Model of Ovarian Cancer

Kathryn M. Kinross, Daniel V. Brown, Margarete Kleinschmidt, Susan Jackson, James Christensen, Carleen Cullinane, Rodney J. Hicks, Ricky W. Johnstone and Grant A. McArthur

Mol Cancer Ther August 1 2011 10 (8) 1440-1449; DOI:10.1158/1535-7163.MCT-11-0240
Preclinical Development

Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition

Misu Lee, Marily Theodoropoulou, Jochen Graw, Federico Roncaroli, Maria Chiara Zatelli and Natalia S. Pellegata

Mol Cancer Ther August 1 2011 10 (8) 1450-1459; DOI:10.1158/1535-7163.MCT-11-0188
Preclinical Development

Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells

Tongrui Liu, Rami Yacoub, LaTonia D. Taliaferro-Smith, Shi-Yong Sun, Tisheeka R. Graham, Ryan Dolan, Christine Lobo, Mourad Tighiouart, Lily Yang, Amy Adams and Ruth M. O'Regan

Mol Cancer Ther August 1 2011 10 (8) 1460-1469; DOI:10.1158/1535-7163.MCT-10-0925
Preclinical Development

Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice

Dipankar Pramanik, Nathaniel R. Campbell, Collins Karikari, Raghu Chivukula, Oliver A. Kent, Joshua T. Mendell and Anirban Maitra

Mol Cancer Ther August 1 2011 10 (8) 1470-1480; DOI:10.1158/1535-7163.MCT-11-0152
Preclinical Development

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

Daniele G. Soares, Miriana S. Machado, Céline J. Rocca, Virginie Poindessous, Djamila Ouaret, Alain Sarasin, Carlos M. Galmarini, João A.P. Henriques, Alexandre E. Escargueil and Annette K. Larsen

Mol Cancer Ther August 1 2011 10 (8) 1481-1489; DOI:10.1158/1535-7163.MCT-11-0252
Preclinical Development

Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282

Dhriti Sooryakumar, Thomas S. Dexheimer, Beverly A. Teicher and Yves Pommier

Mol Cancer Ther August 1 2011 10 (8) 1490-1499; DOI:10.1158/1535-7163.MCT-10-1043
Preclinical Development

Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis

Min Zhu, Romaine E. Saxton, Lillian Ramos, David D. Chang, Beth Y. Karlan, Judith C. Gasson and Dennis J. Slamon

Mol Cancer Ther August 1 2011 10 (8) 1500-1508; DOI:10.1158/1535-7163.MCT-11-0046

Molecular Medicine in Practice

Molecular Medicine in Practice

Rationally Designed Treatment for Solid Tumors with MAPK Pathway Activation: A Phase I Study of Paclitaxel and Bortezomib Using an Adaptive Dose-Finding Approach

Janice M. Mehnert, Antoinette R. Tan, Rebecca Moss, Elizabeth Poplin, Mark N. Stein, Mika Sovak, Kelly Levinson, Hongxia Lin, Michael Kane, Murugesan Gounder, Yong Lin, Weichung Joe Shih, Eileen White, Eric H. Rubin and Vassiliki Karantza

Mol Cancer Ther August 1 2011 10 (8) 1509-1519; DOI:10.1158/1535-7163.MCT-10-0944
Molecular Medicine in Practice

Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies

Sarah-Jane Schramm and Graham J. Mann

Mol Cancer Ther August 1 2011 10 (8) 1520-1528; DOI:10.1158/1535-7163.MCT-10-0901

Correction

Correction

Correction: Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

Mol Cancer Ther August 1 2011 10 (8) 1529-1529; DOI:10.1158/1535-7163.MCT-11-0504

Main menu

User menu

Search

Table of Contents

Highlights

Spotlight on Clinical Response

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Correction

Issue Highlights

Jump to

Articles

Info for

About MCT